Publication

A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer

Banerji, U
; 
Plummer, ER
; 
Moreno, V
; 
Ang, JE
; 
Quinton, A
; 
Drew, Y
; 
Hernandez, T
; 
Roda, D
; 
Carter, Louise
; 
Navarro, A
... show 10 more
Citations
Altmetric:
Abstract
Authors
Banerji, U
Plummer, ER
Moreno, V
Ang, JE
Quinton, A
Drew, Y
Hernandez, T
Roda, D
Carter, Louise
Navarro, A
Kristeleit, RS
Arkenau, HT
Sarker, D
Castellano, DE
Walter, H
Roxburgh, P
Blagden, SP
Anthoney, A
Verdon, I
Jones, RH
Affiliation
Drug Development Unit-The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton,
Description
Date
2019
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Banerji U, Plummer ER, Moreno V, Ang JE, Quinton A, Drew Y, et al. A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer. J Clin Oncol. 2019;37(15_suppl):3095-.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/622437
Embedded videos